Webdisclosure.com

INVENTIVA (EPA:IVA)

23/03/2023 22:00

Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results

Voir tous les communiqués de INVENTIVA

INVENTIVA (EPA:IVA)

14/02/2023 23:00

Correction: Inventiva reports preliminary financial results for Full-Year 2022¹

Voir tous les communiqués de INVENTIVA

INVENTIVA (EPA:IVA)

14/02/2023 22:00

Inventiva reports preliminary financial results for Full-Year 2022¹

Voir tous les communiqués de INVENTIVA

INVENTIVA (EPA:IVA)

26/01/2023 08:00

Results of the votes of the Combined Shareholders’ General Meeting of January 25, 2023

Voir tous les communiqués de INVENTIVA

INVENTIVA (EPA:IVA)

04/01/2023 22:00

Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis

Voir tous les communiqués de INVENTIVA

INVENTIVA (EPA:IVA)

03/01/2023 08:35

Statement of total voting rights and shares forming the company’s share capital as of December 19, 2022

Voir tous les communiqués de INVENTIVA

INVENTIVA (EPA:IVA)

28/11/2022 22:00

Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US

Voir tous les communiqués de INVENTIVA

INVENTIVA (EPA:IVA)

21/11/2022 22:00

Inventiva announces a new Director of the Board of Directors

Voir tous les communiqués de INVENTIVA

INVENTIVA (EPA:IVA)

10/11/2022 22:00

Inventiva reports 2022 Third Quarter Financial Information¹

Voir tous les communiqués de INVENTIVA

INVENTIVA (EPA:IVA)

31/10/2022 08:00

Inventiva provides an update on the development of cedirogant by AbbVie

Voir tous les communiqués de INVENTIVA

1
2
3
4
5
6
7
8
9
10